title: Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.
abstract: CC-1065 is a unique alkylating agent that preferentially binds in the minor groove of double-stranded DNA at adenine-thymine-rich sites. Although it has broad antitumor activity in preclinical models its development was discontinued because of deaths observed during preclinical toxicology studies. Adozelesin is a potent synthetic analog that was chosen for clinical development because it had a similar preclinical antitumor spectrum, but did not produce deaths similar to CC-1065 at therapeutic doses. Phase I evaluations using a variety of Adozelesin treatment schedules have been conducted. This report describes our experience using a multiple dose treatment schedule. Endpoints including antitumor response, maximum tolerated dose, dose limiting toxicity as well as other toxicities and the recommended Phase II starting dose were determined. Adozelesin was given as a 10 minute IV infusion for 5 consecutive days every 21 days or upon recovery from toxicity. The dose range evaluated was 6-30 mcg/m2/day. All patients had refractory solid tumors and had received prior cytotoxic treatment. Thirty-three patients (22 men: 11 women) were entered onto the study and 87 courses were initiated. Dose limiting toxicity was cumulative myelosuppression (leucopenia, thrombocytopenia). The maximum tolerated dose was 30 mcg/m2/day. The only other significant toxicity was an anaphylactoid syndrome that occurred in 2 patients. A partial response was observed in a patient with refractory soft tissue sarcoma. The recommended Phase II starting dose of Adozelesin using a 10 minute IV infusion for 5 consecutive days is 25 mcg/m2/day to be repeated every 4-6 weeks to allow recovery from myelotoxicity, based on our experience. Additional Phase I and II studies with Adozelesin are recommended.
authors.affiliation: Wayne State University School of Medicine, Department of Internal Medicine, Detroit, Michigan 48201, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Foster
authors.forename: P M
authors.initials: PM
authors.lastname: LoRusso
authors.forename: E
authors.initials: E
authors.lastname: Poplin
authors.forename: M
authors.initials: M
authors.lastname: Zalupski
authors.forename: M
authors.initials: M
authors.lastname: Valdivieso
authors.forename: A
authors.initials: A
authors.lastname: Wozniak
authors.forename: L
authors.initials: L
authors.lastname: Flaherty
authors.forename: D A
authors.initials: DA
authors.lastname: Kasunic
authors.forename: R H
authors.initials: RH
authors.lastname: Earhart
authors.forename: L H
authors.initials: LH
authors.lastname: Baker
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001572:Benzofurans; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D053138:Cyclohexenes; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000080890:Duocarmycins; D005260:Female; D006801:Humans; D007211:Indoles; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D001572:Benzofurans; D003509:Cyclohexanecarboxylic Acids; D053138:Cyclohexenes; D000080890:Duocarmycins; D007211:Indoles; C060090:adozelesin